BioCentury | Dec 8, 2020
Product Development

Latest data give Rocket clear path forward in rare CV disease Danon

While an adverse event in the high-dose cohort continues to outline the limits of high volume AAV dosing, Rocket believes that higher-than-expected gene expression levels at lower doses for RP-A501 to treat Danon disease give...
BioCentury | May 1, 2020
Distillery Therapeutics

LAMP2 gene therapy for cardiomyopathy and liver dysfunction in Danon disease

DISEASE CATEGORY: Cardiovascular INDICATION: Cardiomyopathy Adeno-associated viral vector (AAV)-mediated overexpression of LAMP2 could treat Danon disease, a cardiomyopathy caused by loss-of-function LAMP2 point mutations. Danon disease causes cardiac and skeletal muscle weakness and causes multi-organ...
BioCentury | Mar 5, 2019
Financial News

First close for Seventure's new microbiome fund

...fund closed in 2015 with €160 million ($175.3 million) from Novartis AG (NYSE:NVS; SIX:NOVN), Bpifrance, Danone...
BioCentury | Jan 23, 2019
Distillery Therapeutics

Cardiovascular

INDICATION: Cardiomyopathy Patient sample studies suggest CRISPR-mediated editing of the B isoform of LAMP2 could help treat Danon disease, a cardiomyopathy caused by a loss-of-function LAMP2 point mutations. In cardiomyocytes from patients, CRISPR-Cas9-mediated correction of...
BioCentury | Dec 8, 2014
Emerging Company Profile

Eliminate, not recreate

...Funds raised: $23.7 million Investors: Seventure Partners, Lundbeckfond Ventures, Omnes Capital, Shire plc , Groupe Danone...
BioCentury | Jul 31, 2014
Financial News

Hospira beats Street, plans EPO biosimilar submission

...rumored to be in acquisition talks with the medical nutrition unit of food product conglomerate Danone...
BioCentury | Jul 29, 2014
Company News

Hospira said to be mulling bid for Danone unit

...the company is in talks to acquire the medical nutrition unit of food product conglomerate Danone...
...allow Hospira to lower its tax rates by re-domiciling abroad while maintaining a U.S. headquarters. Danone's...
...billion ($1.8 billion), and Hospira recorded adjusted net sales of $4.1 billion for the year. Danone...
BioCentury | Jan 27, 2014
Finance

Going big

...new fund include Natixis Private Equity and Unigrains. Strategic investors such as food product conglomerate Danone...
BioCentury | May 14, 2012
Company News

BioCancell management update

BioCancell Therapeutics Inc. (Tel Aviv:BICL), Jerusalem, Israel Business: Cancer Transitioning: Jonathan Burgin, CFO, to CEO, effective June 1; he succeeds Uri Danon, who will depart WIR Staff cancer...
BioCentury | Jul 6, 2009
Company News

OctoPlus management update

...Drug delivery Hired: Susan Swarte as CFO, formerly finance director of global export at Danone's Danone...
Items per page:
1 - 10 of 12
BioCentury | Dec 8, 2020
Product Development

Latest data give Rocket clear path forward in rare CV disease Danon

While an adverse event in the high-dose cohort continues to outline the limits of high volume AAV dosing, Rocket believes that higher-than-expected gene expression levels at lower doses for RP-A501 to treat Danon disease give...
BioCentury | May 1, 2020
Distillery Therapeutics

LAMP2 gene therapy for cardiomyopathy and liver dysfunction in Danon disease

DISEASE CATEGORY: Cardiovascular INDICATION: Cardiomyopathy Adeno-associated viral vector (AAV)-mediated overexpression of LAMP2 could treat Danon disease, a cardiomyopathy caused by loss-of-function LAMP2 point mutations. Danon disease causes cardiac and skeletal muscle weakness and causes multi-organ...
BioCentury | Mar 5, 2019
Financial News

First close for Seventure's new microbiome fund

...fund closed in 2015 with €160 million ($175.3 million) from Novartis AG (NYSE:NVS; SIX:NOVN), Bpifrance, Danone...
BioCentury | Jan 23, 2019
Distillery Therapeutics

Cardiovascular

INDICATION: Cardiomyopathy Patient sample studies suggest CRISPR-mediated editing of the B isoform of LAMP2 could help treat Danon disease, a cardiomyopathy caused by a loss-of-function LAMP2 point mutations. In cardiomyocytes from patients, CRISPR-Cas9-mediated correction of...
BioCentury | Dec 8, 2014
Emerging Company Profile

Eliminate, not recreate

...Funds raised: $23.7 million Investors: Seventure Partners, Lundbeckfond Ventures, Omnes Capital, Shire plc , Groupe Danone...
BioCentury | Jul 31, 2014
Financial News

Hospira beats Street, plans EPO biosimilar submission

...rumored to be in acquisition talks with the medical nutrition unit of food product conglomerate Danone...
BioCentury | Jul 29, 2014
Company News

Hospira said to be mulling bid for Danone unit

...the company is in talks to acquire the medical nutrition unit of food product conglomerate Danone...
...allow Hospira to lower its tax rates by re-domiciling abroad while maintaining a U.S. headquarters. Danone's...
...billion ($1.8 billion), and Hospira recorded adjusted net sales of $4.1 billion for the year. Danone...
BioCentury | Jan 27, 2014
Finance

Going big

...new fund include Natixis Private Equity and Unigrains. Strategic investors such as food product conglomerate Danone...
BioCentury | May 14, 2012
Company News

BioCancell management update

BioCancell Therapeutics Inc. (Tel Aviv:BICL), Jerusalem, Israel Business: Cancer Transitioning: Jonathan Burgin, CFO, to CEO, effective June 1; he succeeds Uri Danon, who will depart WIR Staff cancer...
BioCentury | Jul 6, 2009
Company News

OctoPlus management update

...Drug delivery Hired: Susan Swarte as CFO, formerly finance director of global export at Danone's Danone...
Items per page:
1 - 10 of 12